Peter P. Pfreundschuh

Chief Financial Officer

Peter is Frequency Therapeutics’ Chief Financial Officer. He joined Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as Chief Financial Officer, Chief Compliance Officer and Corporate Secretary. He brings to Frequency more than 20 years of finance, business development, commercial and public company leadership experience in the life sciences and medical device industries. Prior to joining UroGen, Peter was the CFO of Sucampo Pharmaceuticals Inc., where he co-led the sale of the company to Mallinckrodt, was EVP and CFO of Immunomedics Inc., and was CFO of the heart pump maker, CircuLite Inc. Pfreundschuh also has held senior roles across finance, commercial operations and business development within the pharmaceutical industry at AstraZeneca Pharmaceuticals and Johnson & Johnson. He started his career as an auditor at Ernst & Young, LLP.

Peter is a certified public accountant and holds a Master of Business Administration in finance from Rider University. He has completed master’s coursework in strategic marketing from Northwestern University’s Kellogg School of Management and received his Bachelor of Science in accounting from Rutgers University. Mr. Pfreundschuh is currently on the Boards of Speratus Therapeutics Inc., and GitBasic.